Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05901818 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 10 to 6v4 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2025 to Dec 31, 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2028
    • Start date: Jun 13, 2023 to Apr 1, 2021
    • Secondary endpoints revised (10)
  2. Start date changed from estimate of Jun 6, 2023 to Jun 13, 2023v3
  3. Primary endpoints revised (2)
    • Secondary endpoints revised (10)
    • Eligibility criteria expanded, about 4 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Trial Details
NCT Number NCT05901818
Lead Sponsor Xuanwu Hospital, Beijing
Conditions
(from sponsor)		 Parkinson's Disease
Related terms Parkinson Disease
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov